The R&D team at Bio-Rad AbD Serotec in Munich has developed a new type of specific antibodies.

These new andbodies can be used as a tool both pre-clincally and clinically to develop new therapeutic antibodies. Attana's technology was applied to select and optimize the best of these new antibodies.

The paper describes the different types of these antibody tools, so called anti-idiotypic antibodies. An anti-idiotypic antibody interacts with a therapeutic antibody. An anti-idiotypic antibody of type 1 can only interact with unbound therapeutic antibodies and can thus be used for detecting unbound antibodies in serum. Type 2 can detect both unbound and target-bound therapeutic antibodies therefore determining the total concentration of therapeutic antibodies in the body. In the paper the authors descibe the develepment of a new type of anti-idiotic antibodies, type 3. The type 3 antibody interacts only with receptor-bound therapeutic antibodies, hence it can be used to validate that the therapeutic antibodies interact at the right place in the body. Attana's technology has been applied to develop the desired interaction profile of these typ 3 antibodies to secure a high specificity and interaction properties.

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share prices, but is of general interest for the shareholders and hence should be communicated.

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences.

View | download paper